MX2022007029A - Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. - Google Patents
Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped.Info
- Publication number
- MX2022007029A MX2022007029A MX2022007029A MX2022007029A MX2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A
- Authority
- MX
- Mexico
- Prior art keywords
- host disease
- antibodies
- treatment
- chronic graft
- versus host
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945842P | 2019-12-09 | 2019-12-09 | |
| US202063110111P | 2020-11-05 | 2020-11-05 | |
| PCT/US2020/064010 WO2021119128A1 (en) | 2019-12-09 | 2020-12-09 | Antibodies for the treatment of chronic graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007029A true MX2022007029A (es) | 2022-08-15 |
Family
ID=76330540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007029A MX2022007029A (es) | 2019-12-09 | 2020-12-09 | Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12552869B2 (enExample) |
| EP (1) | EP4073100A4 (enExample) |
| JP (1) | JP2023506779A (enExample) |
| KR (1) | KR20220123004A (enExample) |
| CN (3) | CN115298210A (enExample) |
| AU (1) | AU2020401551A1 (enExample) |
| CA (1) | CA3164126A1 (enExample) |
| IL (1) | IL293705A (enExample) |
| MX (1) | MX2022007029A (enExample) |
| PH (1) | PH12022551401A1 (enExample) |
| WO (1) | WO2021119128A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121219009A (zh) * | 2023-05-17 | 2025-12-26 | 信达克思制药公司 | 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法 |
| AU2024300057A1 (en) * | 2023-07-23 | 2026-01-08 | Incyte Corporation | Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| CN102218070A (zh) * | 2004-12-30 | 2011-10-19 | 索利吉尼克斯公司 | 用二丙酸倍氯米松和泼尼松治疗移植物抗宿主病和白血病 |
| KR20080074120A (ko) | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| JP2010500283A (ja) | 2006-05-31 | 2010-01-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法 |
| US20080114007A1 (en) | 2006-10-31 | 2008-05-15 | Player Mark R | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| RU2547586C2 (ru) | 2008-03-14 | 2015-04-10 | Трансжене С.А. | Антитело против csf-1r |
| US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| UY33801A (es) | 2010-12-13 | 2013-06-28 | Array Biopharma Inc | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III |
| KR102061358B1 (ko) | 2011-10-21 | 2019-12-31 | 트랜스진 에스.에이. | 대식세포 활성화의 조절 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| SG11201705484WA (en) | 2015-02-09 | 2017-08-30 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| US12168054B2 (en) * | 2017-05-19 | 2024-12-17 | Syndax Pharmaceuticals, Inc. | Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody |
-
2020
- 2020-12-09 PH PH1/2022/551401A patent/PH12022551401A1/en unknown
- 2020-12-09 EP EP20899869.0A patent/EP4073100A4/en active Pending
- 2020-12-09 CN CN202080095646.6A patent/CN115298210A/zh active Pending
- 2020-12-09 KR KR1020227023446A patent/KR20220123004A/ko active Pending
- 2020-12-09 JP JP2022535607A patent/JP2023506779A/ja active Pending
- 2020-12-09 CN CN202610407661.9A patent/CN122399012A/zh active Pending
- 2020-12-09 MX MX2022007029A patent/MX2022007029A/es unknown
- 2020-12-09 CN CN202610407659.1A patent/CN122461447A/zh active Pending
- 2020-12-09 IL IL293705A patent/IL293705A/en unknown
- 2020-12-09 WO PCT/US2020/064010 patent/WO2021119128A1/en not_active Ceased
- 2020-12-09 CA CA3164126A patent/CA3164126A1/en active Pending
- 2020-12-09 AU AU2020401551A patent/AU2020401551A1/en active Pending
- 2020-12-09 US US17/783,552 patent/US12552869B2/en active Active
-
2026
- 2026-01-13 US US19/447,470 patent/US20260132210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4073100A4 (en) | 2024-02-14 |
| US20230035183A1 (en) | 2023-02-02 |
| PH12022551401A1 (en) | 2023-08-23 |
| JP2023506779A (ja) | 2023-02-20 |
| WO2021119128A1 (en) | 2021-06-17 |
| CN122461447A (zh) | 2026-07-28 |
| EP4073100A1 (en) | 2022-10-19 |
| US12552869B2 (en) | 2026-02-17 |
| KR20220123004A (ko) | 2022-09-05 |
| AU2020401551A1 (en) | 2022-06-30 |
| CN122399012A (zh) | 2026-07-17 |
| US20260132210A1 (en) | 2026-05-14 |
| CA3164126A1 (en) | 2021-06-17 |
| IL293705A (en) | 2022-08-01 |
| CN115298210A (zh) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| DOP2024000220A (es) | Anticuerpos il-11 | |
| EA201890175A1 (ru) | Антитела к cd40 | |
| EA201990548A1 (ru) | Лечение кластерной головной боли | |
| EA202092605A1 (ru) | Антитела к ил-11ra | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| MX2021014302A (es) | Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa. | |
| EA201891925A1 (ru) | Антитела к cd40 с усиленной агонистической активностью | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| MX2018014560A (es) | Metodos para el tratamiento de la miastenia gravis generalizada refractaria. | |
| EA202191352A1 (ru) | Контроль содержания микроэлементов-металлов во время продукции антител к cd38 | |
| EA201992091A1 (ru) | Анти-c5 антитела и их применение | |
| MX2016014210A (es) | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. | |
| CL2023001052A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
| CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| EA202190162A2 (ru) | Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13 | |
| EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
| EA201791970A1 (ru) | Способ лечения первичного склерозирующего холангита | |
| CO2021000386A2 (es) | Anticuerpos humanizados contra psma | |
| PH12021550991A1 (en) | Monoclonal antibody that specifically binds to cd20 | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. |